Trial Profile
Post Marketing Surveillance on Long Term Drug Use of GIOTRIF Tablets in Patients With Epidermal Growth Factor Receptor Mutation-positive Inoperable or Recurrent Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Oct 2017 Results (n=1602 data cut off: Feb 2017) presented at the 18th World Conference on Lung Cancer
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 29 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.